Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005655 | 0.77 | HTT (0.49) | HTTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL27278396 | 0.73 | HTT (0.67) | HTTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL335332 | 0.71 | — | — | |
| SCHEMBL15836938 | 0.70 | — | — | |
| SCHEMBL892658 | 0.70 | — | — | |
| Lithium Ion SCHEMBL30968154 | 0.68 | HTT (0.51) | HTTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL32678630 | 0.67 | HTT (0.40) | HTTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL32678629 | 0.67 | HTT (0.40) | HTTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL32678632 | 0.67 | HTT (0.40) | HTTKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL31454669 | 0.67 | KDM4E (0.43) | RAB9ANPC1ALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108048-A1 | STING AGONIST COMPOUNDS AND CONJUGATES | SUTRO BIOPHARMA, INC. | 2025-04-03 | — | — | US | disclosed |
| WO-2025029832-A2 | STING AGONIST COMPOUNDS AND CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108048-A1 | STING AGONIST COMPOUNDS AND CONJUGATES | STING1, CGAS, MAVS | HTT 2644/4885KMT2A 3278/4885L3MBTL1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.